For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $46.1 in the prior trading day, Akero Therapeutics Inc (NASDAQ: AKRO) closed at $46.04, down -0.13%. In other words, the price has decreased by -$0.13 from its previous closing price. On the day, 1.31 million shares were traded. AKRO stock price reached its highest trading level at $46.35 during the session, while it also had its lowest trading level at $45.195.
Ratios:
Our goal is to gain a better understanding of AKRO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.66 and its Current Ratio is at 12.66. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.02.
On August 04, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $76.
BofA Securities Upgraded its Neutral to Buy on January 30, 2025, whereas the target price for the stock was revised from $35 to $63.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 01 ’25 when Young Jonathan sold 12,500 shares for $47.76 per share. The transaction valued at 596,978 led to the insider holds 196,898 shares of the business.
Young Jonathan sold 586 shares of AKRO for $25,210 on Sep 11 ’25. The Chief Operating Officer now owns 196,898 shares after completing the transaction at $43.02 per share. On Sep 11 ’25, another insider, Yale Catriona, who serves as the Chief Development Officer of the company, sold 659 shares for $43.02 each. As a result, the insider received 28,350 and left with 90,829 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKRO now has a Market Capitalization of 3682692608 and an Enterprise Value of 2976717312.
Stock Price History:
The Beta on a monthly basis for AKRO is -0.35, which has changed by 0.63552403 over the last 52 weeks, in comparison to a change of 0.1719923 over the same period for the S&P500. Over the past 52 weeks, AKRO has reached a high of $58.40, while it has fallen to a 52-week low of $21.34. The 50-Day Moving Average of the stock is -2.12%, while the 200-Day Moving Average is calculated to be 3.10%.
Shares Statistics:
The stock has traded on average 1.05M shares per day over the past 3-months and 988770 shares per day over the last 10 days, according to various share statistics. A total of 79.92M shares are outstanding, with a floating share count of 70.72M. Insiders hold about 11.59% of the company’s shares, while institutions hold 107.26% stake in the company. Shares short for AKRO as of 1757894400 were 9093866 with a Short Ratio of 8.63, compared to 1755216000 on 9222142. Therefore, it implies a Short% of Shares Outstanding of 9093866 and a Short% of Float of 11.690000000000001.
Earnings Estimates
The dynamic stock of Akero Therapeutics Inc (AKRO) is currently being evaluated by a team of 8.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.97, with high estimates of -$0.92 and low estimates of -$1.06.
Analysts are recommending an EPS of between -$3.58 and -$4.03 for the fiscal current year, implying an average EPS of -$3.72. EPS for the following year is -$4.24, with 7.0 analysts recommending between -$4.01 and -$4.9.
